NO893909L - Fremgangsmaate for fremstilling av terapeutisk aktive imidazol-derivater. - Google Patents

Fremgangsmaate for fremstilling av terapeutisk aktive imidazol-derivater.

Info

Publication number
NO893909L
NO893909L NO89893909A NO893909A NO893909L NO 893909 L NO893909 L NO 893909L NO 89893909 A NO89893909 A NO 89893909A NO 893909 A NO893909 A NO 893909A NO 893909 L NO893909 L NO 893909L
Authority
NO
Norway
Prior art keywords
procedure
preparation
imidazole derivatives
therapeutic active
active imidazole
Prior art date
Application number
NO89893909A
Other languages
English (en)
Norwegian (no)
Other versions
NO893909D0 (no
Inventor
Nigel Stephen Watson
Chuen Chan
Barry Clive Ross
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888823192A external-priority patent/GB8823192D0/en
Priority claimed from GB888823191A external-priority patent/GB8823191D0/en
Priority claimed from GB898902847A external-priority patent/GB8902847D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO893909D0 publication Critical patent/NO893909D0/no
Publication of NO893909L publication Critical patent/NO893909L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO89893909A 1988-10-03 1989-10-02 Fremgangsmaate for fremstilling av terapeutisk aktive imidazol-derivater. NO893909L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB888823192A GB8823192D0 (en) 1988-10-03 1988-10-03 Chemical compounds
GB888823191A GB8823191D0 (en) 1988-10-03 1988-10-03 Chemical compounds
GB898902847A GB8902847D0 (en) 1989-02-09 1989-02-09 Chemical compounds

Publications (2)

Publication Number Publication Date
NO893909D0 NO893909D0 (no) 1989-10-02
NO893909L true NO893909L (no) 1990-04-04

Family

ID=27264106

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89893909A NO893909L (no) 1988-10-03 1989-10-02 Fremgangsmaate for fremstilling av terapeutisk aktive imidazol-derivater.

Country Status (19)

Country Link
US (2) US5013749A (fr)
JP (1) JPH02188571A (fr)
KR (1) KR900006297A (fr)
AU (1) AU628862B2 (fr)
BE (1) BE1003007A3 (fr)
CH (1) CH680442A5 (fr)
DE (1) DE3932887A1 (fr)
DK (1) DK483689A (fr)
ES (1) ES2019163A6 (fr)
FI (1) FI894648A (fr)
FR (1) FR2637183A1 (fr)
GB (1) GB2223224B (fr)
GR (1) GR890100634A (fr)
IT (1) IT1237470B (fr)
LU (1) LU87600A1 (fr)
NL (1) NL8902441A (fr)
NO (1) NO893909L (fr)
PT (1) PT91878B (fr)
SE (1) SE8903226L (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3913725A1 (de) * 1989-04-26 1990-10-31 Basf Ag 1-halogenvinyl-azole und diese enthaltende fungizide und wachstumsregulatoren
IE903606A1 (en) * 1989-10-10 1991-04-24 Glaxo Group Ltd Chemical compounds
SK4112003A3 (en) * 2000-10-12 2004-01-08 Nissan Chemical Ind Ltd Preventives and remedies for complications of diabetes
IL158300A0 (en) * 2001-04-27 2004-05-12 Bristol Myers Squibb Co Bisarylimidazol derivatives and pharmaceutical compositions containing the same
BRPI0509926A (pt) * 2004-04-16 2007-09-18 Warner Lambert Co imidazóis
US7163945B2 (en) * 2004-04-29 2007-01-16 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
WO2006028524A2 (fr) * 2004-04-29 2006-03-16 Pharmix Corporation Compositions et traitements pour l'inhibition de kinase et/ou de hmg-coa reductase
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050282883A1 (en) * 2004-04-29 2005-12-22 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) * 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2626069A4 (fr) 2010-10-06 2014-03-19 Univ Tokyo Médicament destiné à la prévention et au traitement d'un lymph dème

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
WO1987002662A2 (fr) * 1985-10-25 1987-05-07 Sandoz Ag Analogues heterocycliques de mevalonolactone et leurs derives, procedes de production et utilisation en tant que produits pharmaceutiques
JPS6322056A (ja) * 1986-04-30 1988-01-29 サンド・アクチエンゲゼルシヤフト オレフイン性化合物の製造法
DE3800785A1 (de) * 1988-01-09 1989-07-20 Hoechst Ag Substituierte 7-(pyridazin-5-yl)-3,5-dihydroxyheptan(en)- saeuren, ihre entsprechenden (delta)-lactone bzw. derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
NO890522L (no) * 1988-02-25 1989-08-28 Bayer Ag Substituerte imidazolinoner og imidazolinthioner.

Also Published As

Publication number Publication date
DK483689D0 (da) 1989-10-02
FI894648A0 (fi) 1989-10-02
IT8948424A0 (it) 1989-10-02
CH680442A5 (fr) 1992-08-31
AU4243189A (en) 1990-04-05
GB2223224B (en) 1992-01-08
PT91878B (pt) 1995-05-31
AU628862B2 (en) 1992-09-24
GR890100634A (el) 1990-11-29
BE1003007A3 (fr) 1991-10-22
ES2019163A6 (es) 1991-06-01
GB8922212D0 (en) 1989-11-15
IT1237470B (it) 1993-06-07
GB2223224A (en) 1990-04-04
DK483689A (da) 1990-04-04
NL8902441A (nl) 1990-05-01
DE3932887A1 (de) 1990-04-05
SE8903226D0 (sv) 1989-10-02
FR2637183A1 (fr) 1990-04-06
FI894648A (fi) 1990-04-04
SE8903226L (sv) 1990-04-04
US5120848A (en) 1992-06-09
LU87600A1 (fr) 1990-05-15
PT91878A (pt) 1990-04-30
NO893909D0 (no) 1989-10-02
JPH02188571A (ja) 1990-07-24
KR900006297A (ko) 1990-05-07
US5013749A (en) 1991-05-07

Similar Documents

Publication Publication Date Title
NO894630L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinuklidin-derivater.
NO883974L (no) Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater.
NO895086L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
NO904694L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
NO871266L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO901684L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
NO870526D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive dikloranilin-derivater.
NO874032D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive catecholderivater.
NO891293D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazol - og triazol-derivater.
NO893909L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazol-derivater.
NO875488D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater.
NO890155D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive indolpiperidin-forbindelser.
NO891723L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO884176L (no) Fremgangsmaate for fremstilling av terapeutisk aktive amidinoderivater.
NO891114L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive arakidonsyre-derivater.
NO884175D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
NO167802C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazepinderivater.
NO167739C (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive ginkolid-derivater.
NO891046D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,2,4-triazol-derivater.
NO890607L (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyridin-derivater.
NO900972L (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
NO871907D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkenamid-derivater.
NO900942D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater.
NO890724D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetraazaacenaftylen-derivater.
NO890519D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive propanon-derivater.